Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Non-Small Cell Lung Cancer: early-phase trial registry
206 of 455 indexed Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #10 of 28,707 conditions by registered trial count.
455 US clinical trials · 206 currently recruiting · #10 of 28,707 conditions by registered trial count
Non-Small Cell Lung Cancer: 455 US clinical trials tracked, 206 recruiting.
Non-Small Cell Lung Cancer is the subject of 455 registered US clinical trials on ClinicalTrials.gov, 206 of them currently open to new participants. 65 are in Phase 3-4 (later-stage) and 327 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 24 of these trials.
Enrollment posture brief
Registry condition non-small-cell-lung-cancer
OPEN 206 | RECR 45% | LATE 65 | EARLY 327 | RANK #10 | SPON 24
Volume-matched condition peers
Nearest open-share peer: Gastric Cancer (45% recruiting · 159 trials)
Non-Small Cell Lung Cancer lists 206 open slots (45% of 455 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Non-Small Cell Lung Cancer is recruiting above its size-band peers.
206 of 455 indexed trials (45.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Non-Small Cell Lung Cancer trials is spread across many organizations.
AstraZeneca accounts for 24 of 455 trials (5.3%). 242 distinct sponsors appear on at least one study for this condition label.
-
Typical Non-Small Cell Lung Cancer enrolment sits around 105 participants.
Median target enrolment is 105 among the 455 trials that report a genuine target (sentinel values excluded). 212 of those (46.6%) plan for fewer than 100 participants.
-
Non-Small Cell Lung Cancer research is mostly interventional.
414 interventional and 41 observational studies make up this index (91% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
455 total, page 3 of 10
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis Pharmaceuticals
NCT06562192
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience
NCT05267626
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07030257
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
AbbVie
NCT06568939
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Aktis Oncology
NCT07020117
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NextCure
NCT06774963
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Memorial Sloan Kettering Cancer Center
NCT03808337
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Genelux Corporation
NCT06463665
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers
Scientific Institute San Raffaele
NCT06626243
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)
Dizal Pharmaceuticals
NCT06905197
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo
NCT06644768
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
NCT05783622
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
N-Power Medicine
NCT07028489
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
Tango Therapeutics
NCT05887492
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
Study of NEO-201 in Solid Tumors Expansion Cohorts
Precision Biologics
NCT03476681
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
NCT06465329
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics
NCT07216105
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Eutilex
NCT04903873
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
AstraZeneca
NCT06218914
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Wake Forest University Health Sciences
NCT04253964
A Study of KK2269 in Adult Participants With Solid Tumors
Kyowa Kirin Co.
NCT06266299
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Cogent Biosciences
NCT07361562
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
University of Colorado, Denver
NCT03042221
Dabrafenib and/or Trametinib Rollover Study
Novartis Pharmaceuticals
NCT03340506
Exercise as Maintenance Therapy in Advanced Lung Cancer
Indiana University
NCT06513663
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
Dana-Farber Cancer Institute
NCT04789486
LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)
University of California, Davis
NCT06103682
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech
NCT04302025
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Teligene US
NCT05168566
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Ankyra Therapeutics
NCT06171750
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Dren Bio
NCT06999187
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
BeiGene
NCT06685718
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
NCT05227326
TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors
Portage Biotech
NCT04969315
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Merck Sharp & Dohme
NCT06731907
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Memorial Sloan Kettering Cancer Center
NCT01639508
Pulmonary Rehabilitation in Advanced Lung Cancer Survivors
Case Comprehensive Cancer Center
NCT07104630
Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects
University of California, Irvine
NCT06221800
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Avistone Biotechnology Co.
NCT06046495
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Stanford University
NCT04585477
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical
NCT05627960
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
NCT06946797
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
RedCloud Bio
NCT05519293
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
BicycleTx Limited
NCT06933329
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
NCT06150664
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Innate Pharma
NCT05742607
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Massachusetts General Hospital
NCT04900935
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
NCT05657873
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 203 |
| Phase 2 | 124 |
| Phase 3 | 62 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Non-Small Cell Lung Cancer page
455 registered trials, 206 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 206 Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Non-Small Cell Lung Cancer condition card totals 455 registered trials; most-linked intervention Carboplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.